[HTML][HTML] Radionuclides for targeted therapy: physical properties
C Stokke, M Kvassheim, J Blakkisrud - Molecules, 2022 - mdpi.com
A search in PubMed revealed that 72 radionuclides have been considered for molecular or
functional targeted radionuclide therapy. As radionuclide therapies increase in number and …
functional targeted radionuclide therapy. As radionuclide therapies increase in number and …
[HTML][HTML] PSMA-targeting radiopharmaceuticals for prostate cancer therapy: recent developments and future perspectives
M El Fakiri, NM Geis, N Ayada, M Eder, AC Eder - Cancers, 2021 - mdpi.com
Simple Summary One of the most frequently diagnosed cancer in men is adenocarcinoma of
the prostate. Once the disease is metastatic, only very limited treatment options are …
the prostate. Once the disease is metastatic, only very limited treatment options are …
[HTML][HTML] Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy
D Zboralski, A Hoehne, A Bredenbeck… - European journal of …, 2022 - Springer
Purpose Fibroblast activation protein (FAP) is a membrane-bound protease that has limited
expression in normal adult tissues but is highly expressed in the tumor microenvironment of …
expression in normal adult tissues but is highly expressed in the tumor microenvironment of …
[HTML][HTML] Preclinical evaluation of [58mCo]Co-DOTA-PSMA-617 for Auger electron therapy of prostate cancer
C Baun, JH Dam, MG Hildebrandt, JD Ewald… - Scientific Reports, 2023 - nature.com
Prostate-specific membrane antigen (PSMA), highly expressed in prostate cancer, is a
promising target for radionuclide therapy. Auger electron-emitting radionuclides are well …
promising target for radionuclide therapy. Auger electron-emitting radionuclides are well …
[HTML][HTML] Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint …
D Zboralski, F Osterkamp, E Christensen… - European Journal of …, 2023 - Springer
Purpose FAP is a membrane-bound protease under investigation as a pan-cancer target,
given its high levels in tumors but limited expression in normal tissues. FAP-2286 is a …
given its high levels in tumors but limited expression in normal tissues. FAP-2286 is a …
[HTML][HTML] An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of …
Radionuclides are unstable isotopes that mainly emit alpha (α), beta (β) or gamma (γ)
radiation through radiation decay. Therefore, they are used in the biomedical field to label …
radiation through radiation decay. Therefore, they are used in the biomedical field to label …
Radiochemical processing of nuclear-reactor-produced radiolanthanides for medical applications
M Van de Voorde, K Van Hecke, T Cardinaels… - Coordination Chemistry …, 2019 - Elsevier
Several radiolanthanides find their application in nuclear medicine because of their
favorable decay properties, the most important ones being 143 Pr, 149 Pm, 153 Sm, 165 Dy …
favorable decay properties, the most important ones being 143 Pr, 149 Pm, 153 Sm, 165 Dy …
[HTML][HTML] Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy
M Larsson, P Bernhardt, JB Svensson, B Wängberg… - EJNMMI research, 2012 - Springer
Abstract Background Lu-[DOTA 0, Tyr 3]-octreotate (177 Lu-octreotate) is used to treat
neuroendocrine tumors with high somatostatin-receptor expression. 177 Lu-octreotate is …
neuroendocrine tumors with high somatostatin-receptor expression. 177 Lu-octreotate is …
[HTML][HTML] In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy
HS Chan, E De Blois, A Morgenstern, F Bruchertseifer… - PLoS …, 2017 - journals.plos.org
Background Absorbed doses for α-emitters are different from those for β-emitters, as the high
linear energy transfer (LET) nature of α-particles results in a very dense energy deposition …
linear energy transfer (LET) nature of α-particles results in a very dense energy deposition …
Combined targeted radiopharmaceutical therapy and immune checkpoint blockade: From preclinical advances to the clinic
MC Bellavia, RB Patel, CJ Anderson - Journal of Nuclear …, 2022 - Soc Nuclear Med
Immune checkpoint inhibitors (ICIs) have revolutionized cancer care, but many patients with
poorly immunogenic tumors fail to benefit. Preclinical studies have shown that external …
poorly immunogenic tumors fail to benefit. Preclinical studies have shown that external …